Trexquant Investment LP Sells 410,550 Shares of LifeStance Health Group, Inc. $LFST

Key Points

• Trexquant Investment LP reduced its holdings in LifeStance Health Group by 59.3%, now owning approximately 281,487 shares worth $1.87 million.
• Multiple hedge funds purchased new stakes in LifeStance Health Group, with institutional investors collectively owning 85.50% of the company's stock.
• LifeStance Health Group reported a 10.6% year-over-year increase in revenue for the most recent quarter and adjusted its EPS guidance for FY 2025 to -0.18.

Trexquant Investment LP decreased its holdings in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 59.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 281,487 shares of the company's stock after selling 410,550 shares during the quarter. Trexquant Investment LP owned about 0.07% of LifeStance Health Group worth $1,875,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Choreo LLC increased its position in shares of LifeStance Health Group by 6.4% during the first quarter. Choreo LLC now owns 27,420 shares of the company's stock valued at $183,000 after buying an additional 1,661 shares during the period. Invesco Ltd. increased its holdings in LifeStance Health Group by 1.4% during the 1st quarter. Invesco Ltd. now owns 164,384 shares of the company's stock worth $1,095,000 after acquiring an additional 2,238 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in LifeStance Health Group by 2.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 138,781 shares of the company's stock worth $1,023,000 after acquiring an additional 3,305 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in LifeStance Health Group during the 1st quarter worth approximately $31,000. Finally, Hsbc Holdings PLC increased its holdings in LifeStance Health Group by 5.8% during the 1st quarter. Hsbc Holdings PLC now owns 112,189 shares of the company's stock worth $743,000 after acquiring an additional 6,182 shares during the period. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Price Performance

LFST traded down $0.16 during trading on Wednesday, reaching $5.34. The stock had a trading volume of 456,969 shares, compared to its average volume of 2,010,175. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market cap of $2.07 billion, a PE ratio of -106.90 and a beta of 1.17. The business has a 50-day moving average of $4.78 and a 200-day moving average of $5.79. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The company's revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In related news, Director Darren M. Black sold 8,407,643 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the director directly owned 33,524,715 shares in the company, valued at $169,970,305.05. This trade represents a 20.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the insider owned 33,524,715 shares in the company, valued at $169,970,305.05. This represents a 20.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,407,643 shares of company stock worth $103,466,750 over the last ninety days. Insiders own 6.60% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. BTIG Research assumed coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They issued a "buy" rating and a $8.00 price target on the stock. Wall Street Zen upgraded LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, UBS Group upped their target price on LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $8.50.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.